Get started
REGENERON PHARMAC.DL-,001REGENERON PHARMAC.DL-,001REGENERON PHARMAC.DL-,001

REGENERON PHARMAC.DL-,001

No trades
See on Supercharts
Overview
Financials News Ideas Forecast

RGO chart

Key stats

Market capitalization
‪92.41 B‬EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
25.6
Basic EPS (TTM)
33.6EUR
Net income
‪3.58 B‬EUR
Revenue
‪11.88 B‬EUR
Shares float
‪105.09 M‬
Beta (1Y)
0.60

About REGENERON PHARMAC.DL-,001

Sector
Health Technology
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
regeneron.com
Employees (FY)
‪13.45 K‬
Founded
1988
FIGI
BBG003899NB3
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Sparks

Curated watchlists where RGO is featured.

See all sparks 

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange REGENERON PHARMAC.DL-,001 stocks are traded under the ticker RGO.
REGENERON PHARMAC.DL-,001 is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for REGENERON PHARMAC.DL-,001 has a max estimate of 1116.2 EUR and a min estimate of 675.8 EUR.
RGO earnings for the last quarter are 10.96 EUR per share, whereas the estimation was 10.11 EUR resulting in a 8.50% surprise. The estimated earnings for the next quarter are 9.72 EUR per share. See more details about REGENERON PHARMAC.DL-,001 earnings.
REGENERON PHARMAC.DL-,001 revenue for the last quarter amounts to ‪3.18 B‬ EUR despite the estimated figure of ‪3.06 B‬ EUR. In the next quarter revenue is expected to reach ‪2.98 B‬ EUR.
Yes, you can track REGENERON PHARMAC.DL-,001 financials in yearly and quarterly reports right on TradingView.
RGO net income for the last quarter is ‪1.05 B‬ EUR, while the quarter before that showed ‪953.37 M‬ EUR of net income which accounts for 10.20% change. Track more REGENERON PHARMAC.DL-,001 financial stats to get the full picture.
No, RGO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RGO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENERON PHARMAC.DL-,001 stock right from TradingView charts — choose your broker and connect to your account.
RGO reached its all-time high on Feb 28, 2024 with the price of 920.0 EUR, and its all-time low was 3.6 EUR and was reached on Apr 6, 2005.
See other stocks reaching their highest and lowest prices.
As of Apr 23, 2024, the company has ‪13.45 K‬ employees. See our rating of the largest employees — is REGENERON PHARMAC.DL-,001 on this list?
We've gathered analysts' opinions on REGENERON PHARMAC.DL-,001 future price: according to them, RGO price has a max estimate of 1116.16 EUR and a min estimate of 675.89 EUR. Read a more detailed REGENERON PHARMAC.DL-,001 forecast: see what analysts think of REGENERON PHARMAC.DL-,001 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENERON PHARMAC.DL-,001 EBITDA is ‪4.26 B‬ EUR, and current EBITDA margin is 36.36%. See more stats in REGENERON PHARMAC.DL-,001 financial statements.